[{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NMS-01940153E","moa":"ALK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nerviano Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Nerviano Medical Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nerviano Medical Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"NMS-03305293","moa":"Poly [ADP-ribose] polymerase 1 (PARP1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nerviano Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nerviano Medical Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nerviano Medical Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NMS-03305293","moa":"Poly [ADP-ribose] polymerase 1 (PARP1)","graph1":"Oncology","graph2":"Phase I","graph3":"Nerviano Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nerviano Medical Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nerviano Medical Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NMS-03305293","moa":"Poly [ADP-ribose] polymerase 1 (PARP1)","graph1":"Oncology","graph2":"Phase I","graph3":"Nerviano Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nerviano Medical Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nerviano Medical Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"NMS-03305293","moa":"Poly [ADP-ribose] polymerase 1 (PARP1)","graph1":"Oncology","graph2":"Phase I","graph3":"Nerviano Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nerviano Medical Sciences \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Nerviano Medical Sciences \/ Merck & Co"},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"NMS-03597812","moa":"IDH1","graph1":"Oncology","graph2":"Phase I","graph3":"Nerviano Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nerviano Medical Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nerviano Medical Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NMS-03597812","moa":"IDH1","graph1":"Oncology","graph2":"Phase I","graph3":"Nerviano Medical Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nerviano Medical Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nerviano Medical Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Solve Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Nerviano Medical Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nerviano Medical Sciences \/ Nerviano Medical Sciences","highestDevelopmentStatusID":"4","companyTruncated":"Nerviano Medical Sciences \/ Nerviano Medical Sciences"},{"orgOrder":0,"company":"Nerviano Medical Sciences","sponsor":"Italfarmaco S.p.A","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Nerviano Medical Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nerviano Medical Sciences \/ Italfarmaco S.p.A","highestDevelopmentStatusID":"2","companyTruncated":"Nerviano Medical Sciences \/ Italfarmaco S.p.A"}]

Find Clinical Drug Pipeline Developments & Deals by Nerviano Medical Sciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 17, 2025

                          Lead Product(s) : NMS-03305293

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 16, 2025

                          Lead Product(s) : NMS-03305293

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 12, 2024

                          Lead Product(s) : NMS-03597812

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Under the terms of the agreement, ITF will use NMS’s proprietary linker-payload technology to develop a novel peptide-drug conjugate (PDC) to bring first- and best-in-class personalized medicines to cancer patients.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          December 14, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Italfarmaco S.p.A

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          05

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Under the terms of the agreement, SolveTx will use NMS's proprietary linker-payload technology to develop and commercialize novel antibody-drug conjugates (ADCs) for up to four cancer targets selected by SolveTx.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 06, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Solve Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          06

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          November 30, 2022

                          Lead Product(s) : NMS-01940153E

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : NMS-293 has strong potential in combination with a wide variety of DNA-damaging agents, including systemic or targeted chemotherapy (Antibody-Drug Conjugates) or with DNA damage response inhibitors, in numerous tumor types.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 21, 2022

                          Lead Product(s) : NMS-03305293

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Merck & Co

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          08

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          August 30, 2021

                          Lead Product(s) : NMS-03597812

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 02, 2021

                          Lead Product(s) : NMS-03305293

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          iPHEX India
                          Not Confirmed
                          iPHEX India
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 02, 2019

                          Lead Product(s) : NMS-03305293

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank